The National Institutes of Health today announced an agreement with two non-profit organizations to accelerate the development of potential clinical therapies for rare blood cancers.
The cooperative research and development agreement, called The Learning Collaborative (TLC), has been established as a shared commitment to move therapies for rare blood cancers into clinical proof-of-concept studies so that promising treatments can eventually be commercialized. The agreement is among the University of Kansas Medical Center, Kansas City, The Leukemia & Lymphoma Society, the NIH Therapeutics for Rare and Neglected Diseases program, and the Hematology Branch within the National Heart, Lung and Blood Institute.
To read the full, original article click on this link: Kauffman Foundation
